Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers

Trial Profile

Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nalmefene (Primary) ; Nalmefene (Primary)
  • Indications Alcoholism; Opioid abuse
  • Focus Pharmacokinetics
  • Most Recent Events

    • 22 Feb 2018 Results published in an Aegis Therapeutics Media Release
    • 22 Feb 2018 This trial was conducted by the National Institute on Drug Abuse (NIDA) under a clinical trial agreement with Opiant Pharmaceuticals Inc, as reported in an Aegis Therapeutics media release.
    • 10 Jul 2017 Status changed from not yet recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top